A carregar...
Monitoring and Management of Immune‐Related Adverse Events Associated With Programmed Cell Death Protein‐1 Axis Inhibitors in Lung Cancer
Monoclonal antibodies targeting programmed cell death protein‐1 (PD‐1) represent a new treatment paradigm in non‐small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second‐line chemot...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley-Blackwell
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5313273/ https://ncbi.nlm.nih.gov/pubmed/27534573 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0164 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|